[go: up one dir, main page]

CA3265264A1 - Anticorps anti-ccr8 et leurs utilisations - Google Patents

Anticorps anti-ccr8 et leurs utilisations

Info

Publication number
CA3265264A1
CA3265264A1 CA3265264A CA3265264A CA3265264A1 CA 3265264 A1 CA3265264 A1 CA 3265264A1 CA 3265264 A CA3265264 A CA 3265264A CA 3265264 A CA3265264 A CA 3265264A CA 3265264 A1 CA3265264 A1 CA 3265264A1
Authority
CA
Canada
Prior art keywords
ccr8 antibodies
ccr8
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3265264A
Other languages
English (en)
Inventor
David T Brousseau
Gail Walkinshaw
Claudia Witschi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of CA3265264A1 publication Critical patent/CA3265264A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3265264A 2022-08-19 2023-08-18 Anticorps anti-ccr8 et leurs utilisations Pending CA3265264A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263399483P 2022-08-19 2022-08-19
PCT/US2023/072462 WO2024040216A2 (fr) 2022-08-19 2023-08-18 Anticorps anti-ccr8 et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3265264A1 true CA3265264A1 (fr) 2024-02-22

Family

ID=88020873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3265264A Pending CA3265264A1 (fr) 2022-08-19 2023-08-18 Anticorps anti-ccr8 et leurs utilisations

Country Status (7)

Country Link
EP (1) EP4573126A2 (fr)
JP (1) JP2025527535A (fr)
KR (1) KR20250052418A (fr)
CN (1) CN120051493A (fr)
AU (1) AU2023325323A1 (fr)
CA (1) CA3265264A1 (fr)
WO (1) WO2024040216A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025145207A1 (fr) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Polythérapie d'inhibiteur de kras et d'agent de déplétion des treg

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
EP1125584A4 (fr) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd Preparations contenant une proteine betacelluline
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
HUE033349T2 (en) 2003-10-22 2017-11-28 Keck Graduate Inst Procedures for the Synthesis of Heteromultimer Polypeptides in Yeast Using an Hagloid Mating Strategy
WO2006076288A2 (fr) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Constructions d'adn pour l'expression a long terme d'adn nu en injection intravasculaire
TWI845803B (zh) * 2020-01-06 2024-06-21 美商法西尼克斯股份有限公司 抗ｃｃｒ８抗體及其用途
BR112022014623A2 (pt) * 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
CA3172697A1 (fr) * 2020-03-23 2021-09-30 Ruth Yin-Zong LAN Anticorps anti-ccr8 pour le traitement du cancer
EP4267617A1 (fr) * 2020-12-24 2023-11-01 Vib Vzw Liants ccr8 humains
US20250019451A1 (en) 2021-08-20 2025-01-16 Hifibio, Inc. Anti-ccr8 antibodies and uses thereof

Also Published As

Publication number Publication date
KR20250052418A (ko) 2025-04-18
WO2024040216A3 (fr) 2024-04-11
WO2024040216A2 (fr) 2024-02-22
AU2023325323A1 (en) 2025-03-27
EP4573126A2 (fr) 2025-06-25
CN120051493A (zh) 2025-05-27
JP2025527535A (ja) 2025-08-22

Similar Documents

Publication Publication Date Title
IL294330B2 (en) Anti-CCR8 antibodies and their uses
IL319931A (en) Anti-CD122 antibodies and their uses
IL308808A (en) Antibodies against CCR8 and their uses
GB2610467B (en) Anti-CLL1 antibody and application thereof
GB202017058D0 (en) Antibodies and uses thereof
IL307267A (en) ANTI-CD122 antibodies and their uses
IL307940A (en) Anti-ADGRE2 antibodies and their uses
IL310662A (en) Anti-CD161 antibodies and their uses
IL320586A (en) Anti-trem2 antibody and its uses
CA3254156A1 (fr) Anticorps anti-cd84 et leurs utilisations
CA3258731A1 (fr) Nouveaux anticorps anti-lilrb4 et leurs utilisations
IL316510A (en) Anti-B7H3 antibody and its uses
CA3249138A1 (fr) Anticorps anti-ilt3 et leur utilisation
IL323270A (en) Antibody against PTK7 and its uses
IL312584A (en) ANTI-VISTA antibodies and their uses
EP4437000A4 (fr) Anticorps anti-trem2 et ses utilisations
IL307939A (en) Anti-CLEC12A antibodies and uses thereof
CA3265264A1 (fr) Anticorps anti-ccr8 et leurs utilisations
CA3260932A1 (fr) Anticorps spécifiques de cd25 et leurs utilisations
CA3254318A1 (fr) Anticorps anti-ilt2 et leurs utilisations
IL319145A (en) Novel anti-LILRB2 antibodies and their uses
CA3254275A1 (fr) Anticorps modifiés et leurs utilisations
IL304412A (en) Antibodies against cd112r and uses thereof
IL310810A (en) Anti-ACVR2A antibodies and uses thereof
IL308198A (en) Anti-IL-27 antibodies and uses thereof